Diabetes Publish Ahead of Print, published online July 2, 2007

Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes

Rebecca Bailey¹, Jason D. Cooper¹, Lauren Zeitels¹, Deborah J. Smyth¹, Jennie H.M. Yang¹, Neil M. Walker¹, Elina Hyppönen², David B. Dunger³, Elizabeth Ramos-Lopez⁴, Klaus Badenhoop⁴, Sergey Nejentsev¹ and John A. Todd¹*.

¹ Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, UK. ² Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London,

UK.

³ Department of Paediatrics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

⁴ Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, University Hospital, Frankfurt, Germany

Running title: vitamin D CYP27B1 gene in type 1 diabetes

* Corresponding author: Prof John A. Todd, JDRF/WT Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, WT/MRC building, Addenbrooke's Hospital, Cambridge, CB2 0XY, UK. E-mail: john.todd@cimr.cam.ac.uk

Received for publication 15 May 2007 and accepted in revised form 27 June 2007.

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournlas.org.

ABSTRACT

Objective Epidemiological studies have linked vitamin D deficiency with the susceptibility to type 1 diabetes. Higher levels of the active metabolite, 1α ,25-dihydroxyvitamin D, could protect from immune destruction of the pancreatic β cells. 1α ,25-dihydroxyvitamin D is derived from its precursor 25-hydroxyvitamin D by the enzyme 1α -hydroxylase encoded by the CYP27B1 gene, and is inactivated by 24-hydroxylase encoded by the CYP24A1 gene. Our aim was to study the association between the CYP27B1 and CYP24A1 gene polymorphisms and type 1 diabetes.

Research Design and Methods We studied 7,854 patients with type 1 diabetes and 8,758 controls from Great Britain and 2,774 affected families. We studied four *CYP27B1* variants, including common polymorphisms -1260C>A (rs10877012) and +2838T>C (rs4646536), and 16 tag polymorphisms in the CYP24A1 gene.

Results We found evidence of association with type 1 diabetes for *CYP27B1* –1260 and +2838 polymorphisms, which are in perfect linkage disequilibrium. The common C allele of *CYP27B1* -1260 was associated with an increased disease risk in the case-control analysis (OR = 1.07, $P = 2.9 \times 10^{-3}$), and in the fully independent collection of families (RR = 1.11, $P = 6.4 \times 10^{-3}$). The combined support of an association for *CYP27B1* –1260 is $P = 3.8 \times 10^{-6}$. For the CYP24A1 gene we found no evidence of association with type 1 diabetes (multilocus test P = 0.23).

Conclusions The present data provides evidence that common inherited variation in the vitamin D metabolism affects susceptibility to type 1 diabetes.

Type 1 diabetes is strongly inherited and yet exhibits striking epidemiological features such as seasonality in diagnosis, with more cases diagnosed in the autumn and winter months, and a north-south geographical gradient, suggesting inverse correlation between the amount of sunshine and type 1 diabetes incidence (1; 2). Lower serum concentrations of 1α ,25-dihydroxyvitamin D $[1\alpha, 25(OH)_2D]$, the hormonally active form of vitamin D, and of its precursor 25-hydroxyvitamin D [25(OH)D] have been reported at the diagnosis of type 1 diabetes compared to normal controls (3-5). Epidemiological studies indicate that vitamin D supplementation in early childhood is associated with decreased type 1 diabetes incidence (6-8). However, a direct role of impaired vitamin D metabolism in the etiology of type 1 diabetes has not been proven. If vitamin D is a significant factor in type 1 diabetes, then it might be expected that common functional sequence polymorphisms in the genes that influence vitamin D action could predispose to the disease. We have previously studied the gene of the vitamin D receptor (VDR), which binds 1α ,25(OH)₂D and mediates the effects of vitamin D. We found no association between VDR sequence variants and type 1 diabetes, in contrast to some other studies with smaller sample sizes (9), and a recently conducted meta-analysis also found no evidence of association (10).

Several studies have reported associations of type 1 diabetes and other autoimmune diseases with polymorphisms in the CYP27B1 gene on chromosome 12q13.1-q13.3 (11-14), which encodes 1α -hydroxylase, the enzyme that converts 25(OH)D into 1α ,25(OH)₂D. However, these results have not been verified. In the present study we have investigated the association between type 1 diabetes and sequence variants in the CYP27B1 gene. Circulating $1\alpha,25(OH)_2D$ is biologically inactivated through a series of reactions beginning with 24-hydroxylation. Vitamin D 24hydroxylase is encoded by the CYP24A1 gene located on chromosome 20q13.2q13.3. Here, we have for the first time also studied the association between type 1 diabetes and *CYP24A1* polymorphisms.

METHODS

Subjects. We studied a case-control collection comprising 7,854 patients with type 1 diabetes and 8,758 healthy controls from Great Britain. The recruitment of these subjects and sample processing have been described elsewhere (15). We also studied CYP27B1 polymorphisms in a family collection including 2,774 type 1 diabetes families with one or two affected offspring (815 from Great Britain and Northern Ireland, 841 from Finland, 335 from the USA, 360 from Norway and 423 from Romania), providing 3,081 parent-child trio genotypes for CYP27B1 -1260 and 2,198 trio genotypes for CYP27B1 +2838. The collection of all DNA samples has been approved by relevant ethical committees. We obtained written informed consent from all participants.

Genotyping. In the CYP27B1 gene we nucleotide genotyped three single polymorphisms (SNPs), *CYP27B1* 1260C>A (rs10877012, located in the 5' region), CYP27B1 +2838T>C (rs4646536, located in intron 6) that were previously and rs8176345, reported (11-14)а synonymous SNP in exon 5 that we found by sequencing. We used HapMap data (16) to select tag SNPs that capture common variants in the CYP24A1 gene. Of the 111 HapMap SNPs located in the region (NCBI

build 34, coordinates chr 20: 53,450,894..53,482,103), 54 SNPs had minor allele frequency (MAF) > 0.05, and 16 were chosen as tag SNPs that capture association of other common variants with $r^2 > 0.8$. CYP24A1 SNPs were genotyped in up to 5,239 cases and 5,539 controls (exact numbers for each SNP are shown in Table 3). Genotyping was done using TaqMan (Assay-bydesign, Applied Biosystems, Warrington, UK; see Supplementary note available at http://diabetes.diabetesjournals.org). All scored genotypes were by two researchers independently to minimize error. Genotypes of controls and parents did not deviate from Hardy-Weinberg equilibrium above that expected at random (P > 0.05).

DNA sequencing. Direct sequencing of nested PCR products from 32 healthy controls from Great Britain was performed using an Applied Biosystems (ABI) 3700 capillary sequencer (Foster City, CA, USA). Polymorphisms were identified using the Staden Package (http://www.mrc-lmb.cam.ac.uk/pubseq/) and mapped to the NCBI human genome build 35.

Statistical analyses. All statistical analyses were performed within Stata statistical package (http://www.stata.com), using additional Stata routines (http://wwwgene.cimr.cam.ac.uk/clayton/software/). We analyzed cases and controls using logistic regression models (17), adjusting for 12 broad geographical regions, to allow for geographic variation in allele frequencies across Great Britain (18). The families were analyzed using the transmission disequilibrium test (TDT) (19) and conditional logistic regression (17). A score test was used to combine tests from family and case-control studies as described previously (15). We used htstep, htsearch and haptag programs

within Stata 8.2 to select tag SNPs in the CYP24A1 gene. For these SNPs we performed a multilocus test using mlpop program in Stata 8.2, which tests for association between disease and the tag SNPs due to linkage disequilibrium with one or more causal variants in the region. It contrasts allele frequencies of a non-redundant set of tag SNPs between cases and controls by use of Hotelling's T^2 test (20; 21). We did not apply correction for multiple testing.

RESULTS

Association analysis of the *CYP27B1* polymorphisms.

We found evidence that the promoter polymorphism CYP27B1 -1260 is associated with type 1 diabetes in both the case-control $(P = 2.9 \times 10^{-3}; \text{ odds ratio [OR] for C allele})$ = 1.07, 95% confidence interval [CI] = 1.02- 1.13; Table 1) and the family (P = 6.4 x) 10^{-3} ; relative risk [RR] for C allele = 1.11, 95% CI = 1.03 - 1.20: Table 1) collections. Consequently, when we combined evidence from both collections, which are fully independent from each other, the combined test provided statistical support for an association between type 1 diabetes and CYP27B1 - 1260 at $P = 9.08 \times 10^{-5}$ (1 df) and 3.8×10^{-6} (2 df). There was no evidence of regional heterogeneity in the allele frequencies of *CYP27B1* -1260 (F_{11.7261} = 0.86, P = 0.58) in controls from different parts of Great Britain, while we found evidence of population heterogeneity (F_{3 3486} = 3.44, P = 0.016) in allele frequencies among parents from various countries studied.

In contrast to other previously published studies (11-14), we found that intronic SNP *CYP27B1* +2838 was also associated with type 1 diabetes in both collections. The major allele T was associated with increased type 1 diabetes risk in both the case-control ($P = 7.1 \times 10^{-3}$;

OR = 1.08, 95% CI = 1.02 - 1.14; Table 2) and the family ($P = 2.2 \times 10^{-3}$; RR = 1.15, 95% CI = 1.05 - 1.26; Table 2) collections. A combined test provided Pvalues of 2.52 x 10⁻³ (1 df) and 8.47 x 10⁻⁵ (2 df).

We noted that in all population samples that we studied, including controls from Great Britain and parents of the patients from Great Britain and Northern Ireland, Norway or Romania almost perfect there is linkage disequilibrium between SNPs CYP27B1 -1260 and +2838 with D' = 1.0 and r^2 = 0.99 (we obtained lower P-values for CYP27B1 -1260 because more samples were genotyped for this SNP than for genotyping To verify +2838). of CYP27B1 -1260 and +2838 we directly sequenced 376 cases and 533 controls and found complete concordance in the results. This raised the possibility that in the German and Polish population samples studied previously (11-14) there may have been genotyping error in the analysis of *CYP27B1* -1260polymorphism. Therefore, in Cambridge we re-genotyped 120 DNA samples from 36 type 1 diabetes families from the original German laboratory for the two SNPs, obtaining only 88.2% concordance between the two genotype datasets for CYP27B1 –1260, and this problem was compounded by evidence of data handling errors. Contrary to previous analyses (11; 12; 14), in these German samples we found the near-perfect LD between the two SNPs (CYP27B1 -1260 and +2838 SNPs: D' = 1.00 and r^2 = (0.99) as we report here for all other populations studied, indicative of past genotyping and data analysis errors.

Resequencing of the *CYP27B1* gene

We then resequenced 8 kb of the CYP27B1 gene, including all exons, introns and 2 kb 5' and 3' of the gene,

using DNA samples of 32 healthy subjects from Great Britain, in order to test for the presence of an obvious candidate for a causal variant, such as an amino-acid polymorphism changing or a splice mutation. We discovered two novel rare SNPs with MAFs < 0.01, one in the promoter at position -1138 and one in the 3' untranslated region (ss67078180 and ss67078183. respectively; http://www.ncbi.nlm.nih.gov/SNP/). We did not genotype these SNPs because even large samples that we studied here were underpowered to demonstrate association of such rare variants. We also found a synonymous SNP rs8176345 in exon 5 with MAF = 0.03 that was not in linkage disequilibrium with the common CYP27B1 SNPs at positions -1260 and +2838 ($r^2 =$ 0.06 and 0.06, respectively). We genotyped rs8176345 in a subset of the case-control collection comprising 3,040 type 1 diabetes patients and 3,349 controls but obtained no evidence of an association (P = 0.23; OR = 0.87; 95% CI = 0.71 - 1.09). We also identified a common promoter SNP rs3782130 at position -1074 with MAF = 0.33. Since we were unable to develop a working high throughput genotyping assay for this SNP, we sequenced it in 376 cases and 533 controls, and found that it was also in complete linkage disequilibrium with SNPs at positions -1260 and +2838 (r² = 0.99 and 0.97, respectively).

Interaction analyses

We performed case-only gene-gene interaction tests (15) between known type 1 diabetes susceptibility loci and CYP27B1 -1260. We did not undertake the same analyses for CYP27B1 -2838 because these SNPs are in perfect linkage disequilibrium. There was no consistent evidence of an interaction (that is the deviation from a multiplicative model) for the joint effects of CYP27B1 -1260 and INS rs689 (-23HphI), PTPN22 rs2476601 (Arg620Trp) or CTLA4 rs3087243 (Supplementary Table 1).

However, there was some evidence for an interaction with HLA-DRB1 (Supplementary Table 1), but when we analyzed CYP27B1 -1260 stratified by specific HLA-DRB1 genotypes, we found that risk ratios were not consistent between the case-control and family collections (Supplementary Table 2). Therefore, we conclude that in conferring risk of type 1 diabetes CYP27B1 does not interact with the previously known disease genes. We conducted a similar interaction analysis for CYP27B1 -1260 and seven VDR SNPs (FokI, ApaI, BsmI, TagI. rs2544043, rs12721366 and rs4303288), which previously showed marginal or little evidence of an association with type 1 diabetes (9; 10). However, we found no evidence of an interaction (Supplementary Table 1). We compared the relative risk of type 1 diabetes conferred by the CYP27B1 -1260 in the different populations that we studied here, but found no evidence of heterogeneity above that expected at random $(\chi_6^2 = 3.11, P = 0.79)$. We also tested CYP27B1 -1260 for age-atdiagnosis and sex effects in a case-only analysis but did not find evidence for these (Supplementary Table 1), or for parent-of-origin effect in the affected families (P = 0.76).

Analysis of the CYP24A1 gene

In the case-control collection we tested 16 tag SNPs that capture association of the common variants that were present in the CYP24A1 gene in HapMap (Table 3). A multilocus test revealed no evidence of association between *CYP24A1* polymorphisms and type 1 diabetes (P = 0.23). Therefore, we did not undertake follow-up genotyping of any of the *CYP24A1* polymorphisms in additional cases and controls or families.

DISCUSSION

The present study provides the first evidence of association between *CYP27B1* polymorphisms and type 1 diabetes in a fully validated analysis. Our results in the present report indicate what appears to have been technical and analytical errors in the previous studies (11-14). Nevertheless, these initial reports did contribute to our motivation to carry out the current analysis of *CYP27B1* in type 1 diabetes.

Taking into account prior epidemiological and experimental links between vitamin D and type 1 diabetes (3-8; 22-27) and the association between CYP27B1 and type 1 diabetes that we established here, we suggest that common inherited variation in the CYP27B1 gene affects vitamin D metabolism and is an etiological factor predisposing to type 1 diabetes. Rare CYP27B1 mutations that completely inactivate 1α -hydroxylase are known to cause vitamin D-dependent rickets type I (OMIM 264700), characterized by low concentrations of 1α ,25(OH)₂D (28; 29). We hypothesize that the presence of the CYP27B1 -1260 C allele, or another variant in linkage disequilibrium with it (such as two that we have studied here, CYP27B1 +2838 in intron 6 and rs3782130 in the 5' region) reduces the level of the active 1α hydroxylase and conversion of 25(OH)D to $1\alpha, 25(OH)_2D$, leading to increased predisposition to type 1 diabetes. Recently, preliminary data have suggested that type 1 diabetes patients carrying at CYP27B1 -1260 risk genotype CC had lower CYP27B1 mRNA levels in the peripheral blood mononuclear cells compared to healthy controls with the CC genotype (30). Functional roles of *CYP27B1* the polymorphisms should be investigated in further experiments, evaluating their effects on 1α -hydroxylase activity and 1α ,25(OH)₂D concentration, in particular, in the immune cells, such as dendritic cells and

monocytes, that underpin immune responses (31; 32).

Given our evidence that variation in the CYP27B1 gene etiologically contributes to type 1 diabetes risk, other genes that control vitamin D metabolism are also biologically plausible candidates and studies of their association with type diabetes are required. Here we 1 investigated the CYP24A1 gene that encodes vitamin D 24-hydroxylase, an enzyme that inactivates $1\alpha.25(OH)_2D$. and found no evidence of association. Studies of CYP27A1 or CYP2R1 that encode vitamin D 25-hydroxylases, and of the vitamin D-binding protein gene (33; 34) are also needed.

In the immune system $1\alpha.25(OH)$ ₂D has been shown to suppress production of the IL-12, IL-2, TNF α and IFN γ cytokines and activate expression of TGF^{β1} and IL-4 cytokines, thereby inhibiting Th1-type responses, and to induce regulatory T cells (35). It can also regulate differentiation and maturation of dendritic cells critical in induction of T-cell mediated immune responses These (36). immunomodulatory effects may explain the reported protective effects of vitamin D in type 1 diabetes (37). In the animal models 1α , 25(OH)₂D₃ and its analogues have been effective in prevention of autoimmune diabetes (23-27), as well as of other autoimmune diseases (38-42). Epidemiological studies in humans also indicate that intake of vitamin D and its high circulating levels are associated with a lower risk of rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (43-45). Genetic studies reported association of the CYP27B1 polymorphisms with Addison's disease, Hashimoto's thyroiditis and Graves' disease (12; 13), but these results await confirmation. The possibility that CYP27B1 and 1α ,25(OH)₂D may be

involved in multiple autoimmune diseases suggests that effects of vitamin D on type 1 diabetes involve immune regulation, but this does not rule out additional effects, such as protection of pancreatic beta cells and their functions.

Our study indicates that genetic variation in the vitamin D metabolism is an etiological factor in type 1 diabetes. This evidence justifies further experiments investigating molecular and cellular actions of vitamin D and mechanisms of its protective effect in type 1 diabetes. Epidemiological studies indicate that vitamin D supplementation in early childhood may reduce type 1 diabetes risk (6-8). Given that vitamin D insufficiency is more common among children and young adults than was previously thought (46), its correction may be a viable approach to prevent type 1 diabetes or delay its development.

ACKNOWLEDGEMENTS

This work was funded by the Wellcome Trust and the Juvenile Diabetes Research Foundation International. S. Nejentsev is a Diabetes Research and Wellness Foundation Non-Clinical Fellow. E. Hyppönen is a Department of Health (UK) Public Health Career Scientist. E. Ramos-Lopez and K. Badenhoop were supported by the European foundation for the study of Diabetes (EFSD). We acknowledge the participation of all of the patients, controls subjects and family members. We thank the Human Biological Data Interchange and Diabetes UK for the USA and UK multiplex families, respectively; the Norwegian Study Group for Childhood Diabetes, D. Undlien and K. Rønningen for the collection of the Norwegian families, C. Guia and C. Ionescu-Tirgoviste for the collection of the Romanian families, T. Siegmund for the collection of the German families, B. Widmer for the collection of the British type

1 diabetes patients. We acknowledge use of DNA from the British 1958 Birth Cohort collection (R. Jones, S. Ring, W. McArdle and M. Pembrey), funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant

068545/Z/02, and we thank D. Strachan and P. Burton for their help. We thank S. Nutland the help in preparing DNA samples and C. Power for the advice on this manuscript.

REFERENCES

1. Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK: Environmental triggers and determinants of type 1 diabetes. *Diabetes* 54:S125-136, 2005

2. Dahlquist G, Mustonen L: Childhood onset diabetes - time trends and climatological factors. *Int J Epidemiol* 23:1234-1241, 1994

3. Baumgartl HJ, Standl E, Schmidt-Gayk H, Kolb HJ, Janka HU, Ziegler AG: Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus. *Diabetes Res* 16:145-148, 1991

4. Pozzilli P, Manfrini S, Crino A, Picardi A, Leomanni C, Cherubini V, Valente L, Khazrai M, Visalli N: Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes. *Horm Metab Res* 37:680-683, 2005

5. Littorin B, Blom P, Scholin A, Arnqvist HJ, Blohme G, Bolinder J, Ekbom Schnell A, Eriksson JW, Gudbjornsdottir S, Nystrom L, Ostman J, Sundkvist G: Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). *Diabetologia* 49:2847-2852, 2006

6. EURODIAB: Vitamin D supplement in early childhood and risk for Type I (insulindependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group. *Diabetologia* 42:51-54, 1999

7. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet* 358:1500-1503, 2001

8. Stene LC, Joner G: Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. *Am J Clin Nutr* 78:1128-1134, 2003

9. Nejentsev S, Cooper JD, Godfrey L, Howson JM, Rance H, Nutland S, Walker NM, Guja C, Ionescu Tirgoviste C, Savage DA, Undlien DE, Ronningen KS, Tuomilehto Wolf E, Tuomilehto J, Gillespie KM, Ring SM, Strachan DP, Widmer B, Dunger D, Todd JA: Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. *Diabetes* 53:2709-2712, 2004

10. Guo SW, Magnuson VL, Schiller JJ, Wang X, Wu Y, Ghosh S: Meta-analysis of vitamin D receptor polymorphisms and type 1 diabetes: a HuGE review of genetic association studies. *Am J Epidemiol* 164:711-724, 2006

11. Lopez ER, Regulla K, Pani MA, Krause M, Usadel KH, Badenhoop K: CYP27B1 polymorphisms variants are associated with type 1 diabetes mellitus in Germans. *J Steroid Biochem Mol Biol* 90:155-157, 2004

12. Lopez ER, Zwermann O, Segni M, Meyer G, Reincke M, Seissler J, Herwig J, Usadel KH, Badenhoop K: A promoter polymorphism of the CYP27B1 gene is associated with

Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 diabetes mellitus in Germans. *Eur J Endocrinol* 151:193-197, 2004

13. Kurylowicz A, Badenhoop K: CYP27B1 gene polymorphism is associated with Graves' disease in a Polish population study. *Thyroid* 15:1107-1108, 2005

14. Pani MA, Regulla K, Segni M, Krause M, Hofmann S, Hufner M, Herwig J, Pasquino AM, Usadel KH, Badenhoop K: Vitamin D 1alpha-hydroxylase (CYP1alpha) polymorphism in Graves' disease, Hashimoto's thyroiditis and type 1 diabetes mellitus. *Eur J Endocrinol* 146:777-781, 2002

15. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, Vella A, Nutland S, Rance HE, Maier L, Barratt BJ, Guja C, Ionescu Tirgoviste C, Savage DA, Dunger DB, Widmer B, Strachan DP, Ring SM, Walker N, Clayton DG, Twells RC, Gough SC, Todd JA: Replication of an association between the lymphoid tyrosine phosphatase locus (*LYP/PTPN22*) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. *Diabetes* 53:3020-3023, 2004

16. International HapMap Consortium: A haplotype map of the human genome. *Nature* 437:1299-1320, 2005

17. Cordell HJ, Clayton DG: A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. *Am J Hum Genet* 70:124-141, 2002

18. Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, Maier LM, Smink LJ, Lam AC, Ovington NR, Stevens HE, Nutland S, Howson JM, Faham M, Moorhead M, Jones HB, Falkowski M, Hardenbol P, Willis TD, Todd JA: Population structure, differential bias and genomic control in a large-scale, case-control association study. *Nat Genet* 37:1243-1246, 2005

19. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet* 52:506-516, 1993

20. Chapman JM, Cooper JD, Todd JA, Clayton DG: Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power. *Hum Hered* 56:18-31, 2003

21. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, Jones R, Ring SM, McArdle W, Pembrey ME, Strachan DP, Dunger DB, Twells RC, Clayton DG, Todd JA: Localization of a Type 1 Diabetes Locus in the IL2RA/CD25 Region by Use of Tag Single-Nucleotide Polymorphisms. *Am J Hum Genet* 76:5, 2005

22. Brekke HK, Ludvigsson J: Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study. *Pediatr Diabetes* 8:11-14, 2007

23. Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R: 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. *Diabetes* 41:1491-1495, 1992 24. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R: Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. *Diabetologia* 37:552-558, 1994

25. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L: A 1alpha,25dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. *Diabetes* 51:1367-1374, 2002

26. Zella JB, McCary LC, DeLuca HF: Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. *Arch Biochem Biophys* 417:77-80, 2003

27. Mathieu C, Adorini L: The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. *Trends Mol Med* 8:174-179, 2002

28. Kitanaka S, Takeyama K, Murayama A, Sato T, Okumura K, Nogami M, Hasegawa Y, Niimi H, Yanagisawa J, Tanaka T, Kato S: Inactivating mutations in the 25hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. *N Engl J Med* 338:653-661, 1998

29. Wang JT, Lin CJ, Burridge SM, Fu GK, Labuda M, Portale AA, Miller WL: Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. *Am J Hum Genet* 63:1694-1702, 1998

30. Ramos-Lopez E, Bruck P, Jansen T, Pfeilschifter JM, Radeke HH, Badenhoop K: CYP2R1-, CYP27B1- and CYP24-mRNA expression in German type 1 diabetes patients. *J Steroid Biochem Mol Biol* 103:807-810, 2007

31. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science* 311:1770-1773, 2006

32. Overbergh L, Stoffels K, Waer M, Verstuyf A, Bouillon R, Mathieu C: Immune regulation of 25-hydroxyvitamin D-1alpha-hydroxylase in human monocytic THP1 cells: mechanisms of interferon-gamma-mediated induction. *J Clin Endocrinol Metab* 91:3566-3574, 2006

33. Pani MA, Donner H, Herwig J, Usadel KH, Badenhoop K: Vitamin D binding protein alleles and susceptibility for type 1 diabetes in Germans. *Autoimmunity* 31:67-72, 1999

34. Ongagna JC, Pinget M, Belcourt A: Vitamin D-binding protein gene polymorphism association with IA-2 autoantibodies in type 1 diabetes. *Clin Biochem* 38:415-419, 2005

35. Jones G, Strugnell SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. *Physiol Rev* 78:1193-1231, 1998

36. Penna G, Adorini L: 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. *J Immunol* 164:2405-2411, 2000

37. Mathieu C, Gysemans C, Giulietti A, Bouillon R: Vitamin D and diabetes. *Diabetologia* 48:1247-1257, 2005

38. Lemire JM, Archer DC: 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. *J Clin Invest* 87:1103-1107, 1991

39. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. *Proc Natl Acad Sci U S A* 93:7861-7864, 1996

40. Larsson P, Mattsson L, Klareskog L, Johnsson C: A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. *Clin Exp Immunol* 114:277-283, 1998

41. Cantorna MT, Hayes CE, DeLuca HF: 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. *J Nutr* 128:68-72, 1998

42. Cantorna MT, Munsick C, Bemiss C, Mahon BD: 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. *J Nutr* 130:2648-2652, 2000

43. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *Jama* 296:2832-2838, 2006

44. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG: Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheum* 50:72-77, 2004

45. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS: Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev* 5:114-117, 2006

46. Holick MF: Resurrection of vitamin D deficiency and rickets. *J Clin Invest* 116:2062-2072, 2006

	Cases, n (%)	Controls, n (%)	OR (95% CI)	<i>P</i> -value
Allele				
А	4,999 (31.8)	5,836 (33.3)	1.00 (reference)	
С	10,709 (68.2)	11,680 (66.7)	1.07 (1.02-1.13)	2.9 x 10 ⁻³ *
Genotype				
A/A	767 (9.8)	999 (11.4)	1.00 (reference)	
C/A	3,465 (44.1)	3,838 (43.8)	1.20 (1.08-1.33)	
C/C	3,622 (46.1)	3,921 (44.8)	1.22 (1.10-1.36)	9.6 x 10 ⁻⁴ †
	Transmitted, n (%)	Untransmitted, n (%)	RR (95% CI)	<i>P</i> -value
Allele C	1,405 (52.6)	1,264 (47.4)	1.11 (1.03-1.20)	6.4 x 10 ⁻³ ‡
Genotype				
A/A	274 (8.9)	989 (10.7)	1.00 (reference)	
C/A	1,369 (44.4)	4,055 (43.9)	1.27 (1.08-1.48)	
C/C	1,438 (46.7)	4,199 (45.4)	1.33 (1.12-1.58)	3.9 x 10 ⁻³ §

Table 1. *CYP27B1* –1260 allele and genotype frequencies and association test results in 7,854 case and 8,758 control genotypes and 3,081 parent-child trio genotypes.

For the case-control collection a full genotype model was significantly different from the model of multiplicative allelic effects (likelihood-ratio test, $\chi_1^2 = 5.0$, P = 0.025).

* 1 df likelihood ratio test for multiplicative allelic effects

† 2 df likelihood ratio test for genotype effects

‡ Transmission Disequilibrium Test

§ 2 df likelihood-ratio test for the full genotype model; genotypes for the family-based pseudocontrols were estimated as described previously (17)

	Cases, n (%)	Controls, n (%)	OR (95% CI)	P-value
Allele				
С	3,576 (32.2)	5,031 (33.8)	1.00 (reference)	
Т	7,528 (67.8)	9,839 (66.2)	1.08 (1.02-1.14)	7.1 x 10 ^{-3 *}
Genotype				
C/C	573 (10.3)	877(11.8)	1.00 (reference)	
T/C	2,430 (43.8)	3,277 (44.1)	1.16 (1.03-1.31)	
T/T	2,549 (45.9)	3,281 (44.1)	1.20 (1.07-1.36)	0.010 †
	Transmitted, n (%)	Untransmitted, n (%)	RR (95% CI)	<i>P</i> -value
Allele T	995 (53.6)	863 (46.4)	1.15 (1.05-1.26)	2.2 x 10 ⁻³ ‡
Genotype				
C/C	182 (8.3)	709 (10.8)	1.00 (reference)	
T/C	996 (45.3)	2,926 (44.4)	1.27 (1.06-1.53)	
T/T	1,020 (46.4)	2,959 (44.9)	1.36 (1.11-1.67)	6.1 x 10 ⁻⁴ §

Table 2. *CYP27B1* +2838 allele and genotype frequencies and association test results in 5,552 case and 7,435 control genotypes and 2,198 parent-child trio genotypes.

For the case-control collection a model of multiplicative allelic effects was not significantly different from the full genotype model (likelihood-ratio test, $\chi_1^2 = 1.9$, P = 0.17).

* 1 df likelihood ratio test for multiplicative allelic effects

† 2 df likelihood ratio test for genotype effects

‡ Transmission Disequilibrium Test

§ 2 df likelihood-ratio test for the full genotype model; genotypes for the family-based pseudo-controls were estimated as described previously (17)

CYP24A1	Alleles	Minor		Cases				Controls						
polymorphism	n 1/2	allele	11 (%)	12 (%)	22 (%)	Total	11 (%)	12 (%)	22 (%)	Total	MAF	OR	(95%	CI)
rs2762928	T/A	Т	92 (1.8)	1,187 (23.5)	3,775 (74.7)	5,054	106 (1.9)	1,283 (23.2)	4,150 (74.9)	5,539	0.13	1.01 (0.93 -	1.09)
rs2585428	G/A	Α	1,453 (29.1)	2,441 (48.9)	1,101 (22.0)	4,995	1,552 (28.0)	2,739 (49.5)	1,247 (22.5)	5,538	0.47	0.98 (0.92 -	1.03)
rs912505	G/A	G	205 (4.1)	1,735 (34.7)	3,055 (61.2)	4,995	227 (4.2)	1,829 (33.4)	3,413 (62.4)	5,469	0.21	1.04 (0.97 -	1.11)
rs8124792	G/A	Α	4,616 (90.1)	492 (9.6)	14 (0.27)	5,122	4,680 (89.6)	523 (10.0)	21 (0.40)	5,224	0.05	0.95 (0.84 -	1.08)
rs4809956	T/C	Т	175 (3.5)	1,613 (31.8)	3,289 (64.8)	5,077	180 (3.4)	1,707 (32.2)	3,417 (64.4)	5,304	0.19	1.00 (0.93 -	1.07)
rs2426498	C/G	G	3,816 (75.0)	1,182 (23.2)	87 (1.7)	5,085	4,124 (75.1)	1,258 (22.9)	107 (2.0)	5,489	0.13	0.99 (0.91 -	1.07)
rs13038432	G/A	G	29 (0.64)	668 (14.7)	3,854 (84.7)	4,551	30 (0.59)	690 (13.5)	4,404 (86.0)	5,124	0.07	1.10 (0.98 -	1.22)
rs2245153	T/C	C	3,066 (64.3)	1,493 (31.3)	207 (4.3)	4,766	3,274 (65.4)	1,533 (30.6)	198 (4.0)	5,005	0.19	1.05 (0.98 -	1.13)
rs6022999	G/A	G	258 (5.2)	1,719 (34.8)	2,970 (60.0)	4,947	259 (4.8)	1,956 (36.2)	3,188 (59.0)	5,403	0.23	0.98 (0.92 -	1.05)
rs6127118	G/A	А	2,670 (56.7)	1,769 (37.5)	273 (5.8)	4,712	3,022 (59.7)	1,761 (34.8)	277 (5.5)	5,060	0.23	1.10 (1.03 -	1.18)
rs3787557	T/C	C	3,522 (74.4)	1,135 (24.0)	80 (1.7)	4,737	3,772 (74.6)	1,175 (23.2)	108 (2.1)	5,055	0.14	1.00 (0.92 -	1.09)
rs2762939	C/G	C	258 (5.6)	1,788 (38.5)	2,596 (55.9)	4,642	309 (6.1)	1,909 (37.4)	2,888 (56.6)	5,106	0.25	1.01 (0.94 -	1.08)

 Table 3. Analysis of 16 tag polymorphisms of the CYP24A1 gene in type 1 diabetes cases and controls.

15

rs6068810	T/G	Ţ	8 (0.17)	297 (6.3)	4,447 (93.6) 4,7:	52 6 (0.12)	349 (7.2)	4,489 (92.7) 4,844	0.04	0.87 (0.75 - 1.02)
rs2181874	G/A	А	2,848 (57.5)	1,819 (36.7)	289 (5.8) 4,9:	56 3,102 (57.0)	1,994 (36.6)	346 (6.4) 5,442	0.25	0.97 (0.91 - 1.03)
rs2244719	T/C	C	1,361 (26.9)	2,629 (51.9)	1,074 (21.2) 5,0	54 1,506 (27.5)	2,734 (49.8)	1,246 (22.7) 5,486	0.48	0.97 (0.92 - 1.03)
rs2248359	T/C	Т	919 (17.54)	2,430 (46.4)	1,890 (36.1) 5,2	39 817 (15.3)	2,592 (48.7)	1,918 (36.0) 5,327	0.40	1.05 (0.99 - 1.11)

Multilocus test (20; 21), $F_{16,11183} = 1.24$, P = 0.23.

MAF, minor allele frequency; OR, odds ratio for a minor allele; 95% CI, 95% confidence interval